Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Multiple-Dose Study of Efmarodocokin alfa (RO7021610) in Japanese Patients with Ulcerative Colitis
jRCT2080224649Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in autoimmune colitis comparing Efmarodocokin alfa IV with Placebo IV (2 arms). Primary endpoint: Primary safety and tolerability endpoints. Started Apr 2019; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224649.